2024新澳门免费原料网香港开吗-免费完整资料

News

2020-10-13XLifeSc Announces that Axis Receives FDA Clearance for TCR-T Cell Therapy IND to Initiate Clinical Trials in the USA

As announced by Athenex, Inc. (NASDAQ: ATNX), Axis Therapeutics Limited, a joint venture between Athenex and Xiangxue Life Sciences Limited (“XLifeSc"), the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for TCRT-ESO-A2, an autologous T cell rec...
see details >>
2020-10-13FDA Acceptance for Filing of U.S. NDA for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer with Priority Review

Guangzhou Xiangxue Pharmaceutical Co., Ltd. (“Xiangxue”) received news from Athenex, Inc. (Nasdaq: ATNX) that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for oral paclitaxel and encequidar (Oral Paclitaxel) for the treatment of meta...
see details >>
2019-12-17Guangzhou Xiangxue Pharmaceutical Expands its Strategic Partnership with Athenex Inc. through a Licensing Agreement for the Product Candidates Oral Paclitaxel, Oral Irinotecan, and Tirbanibulin Ointment, in China

Guangzhou Xiangxue Pharmaceutical Co., Ltd. (“Xiangxue”) has expandedits strategic partnership with Athenex, Inc. (Nasdaq: ATNX) to exclusively developand commercialize Athenex’s oncology product candidates Oral Paclitaxel (boththe capsule and the tablet formulations), Oral Irinotecan, as well as...
see details >>
2019-10-17XLifes once again named “top 50 biotechnology enterprises” of GAB

Source: Guangdong Medical Valley On October 16, the second award ceremony for the “top 50 biotechnology innovation enterprises in Guangdong-Hong Kong-Macao Greater Bay Area "（“GBA"）was held in Guangzhou. Xiangxue Life Sciences, Ltd (herein after referred to as “XLifes"), a subsidiary of Gua...
see details >>

目前在第1页, 共有3页, 共有11条记录第一页上一页 1 2 3 下一页最后一页 跳转到页

800-888-6655 No. 2, Jinfengyuan Road, Science City, Guangzhou Economic and Technological Development Zone 020-22211555: XPH Group; XLifeSc; Pharmaceutical; TCM Resources

2020-10-13XLifeSc Announces that Axis Receives FDA Clearance for TCR-T Cell Therapy IND to Initiate Clinical Trials in the USA

2020-10-13FDA Acceptance for Filing of U.S. NDA for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer with Priority Review

2019-12-17Guangzhou Xiangxue Pharmaceutical Expands its Strategic Partnership with Athenex Inc. through a Licensing Agreement for the Product Candidates Oral Paclitaxel, Oral Irinotecan, and Tirbanibulin Ointment, in China

2019-10-17XLifes once again named “top 50 biotechnology enterprises” of GAB